AI English summary of an SEC filing — figures as filed
Johnson & Johnson JNJJ&J said it announced a Proposed Plan of Reorganization to resolve all current and future U.S. ovarian cancer talc claims, with a present value of approximately $6.475 billion to be paid over 25 years (nominal value of approximately $8.4 billion, discounted at 4.4%). Mesothelioma and state consumer protection claims are excluded.
Key points
AI summaryJ&J said it announced a Proposed Plan of Reorganization to resolve all current and future U.S. ovarian cancer talc claims, with a present value of approximately $6.475 billion to be paid over 25 years (nominal value of approximately $8.4 billion, discounted at 4.4%). Mesothelioma and state consumer protection claims are excluded.
The company said it recorded an incremental charge of approximately $2.7 billion to account for these settlements and the proposed comprehensive resolution, and that its total reserve as of the end of Q1 2024 was approximately $11 billion at present value (approximately $13.7 billion nominal value).
Johnson & Johnson said it treats the plan as a recognized subsequent event and has reduced its previously reported GAAP net earnings for Q1 2024 from $5.4 billion to $3.3 billion, and its earnings per share from $2.20 to $1.34.
The company said there is no impact on Adjusted Earnings, Adjusted EPS or Adjusted Operational EPS for Q1 2024. Adjusted net earnings from continuing operations were presented at $6,580 million, and adjusted diluted earnings per share were $2.71.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Johnson & Johnson Proposed Plan of Reorganization for Ovarian Cancer Talc Litigation
J&J said it announced a Proposed Plan of Reorganization to resolve all current and future U.S. ovarian cancer talc claims, with a present value of approximately $6.475 billion to be paid over 25 years (nominal value of approximately $8.4 billion, discounted at 4.4%). Mesothelioma and state consumer protection claims are excluded.
Source · Based on the filing body and exhibits
Additional Talc Charge and Total Reserve
The company said it recorded an incremental charge of approximately $2.7 billion to account for these settlements and the proposed comprehensive resolution, and that its total reserve as of the end of Q1 2024 was approximately $11 billion at present value (approximately $13.7 billion nominal value).
Source · Based on the filing body and exhibits
GAAP Net Earnings and EPS Revised for Q1
Johnson & Johnson said it treats the plan as a recognized subsequent event and has reduced its previously reported GAAP net earnings for Q1 2024 from $5.4 billion to $3.3 billion, and its earnings per share from $2.20 to $1.34.
Source · Based on the filing body and exhibits
No Impact on Adjusted Measures and Adjusted Earnings
The company said there is no impact on Adjusted Earnings, Adjusted EPS or Adjusted Operational EPS for Q1 2024. Adjusted net earnings from continuing operations were presented at $6,580 million, and adjusted diluted earnings per share were $2.71.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…